The main objective of this study was to provide further information concerning the validity of patient-reported executive function (EF) in survivors of primary brain tumor (PBT) compared with a report provided by each patient’s caregiver.
Forty survivors of PBT, 40 non-cancer controls and their proxies completed an assessment of functional executive disorders (e.g., planning, inhibition, shifting, action initiation). Comparisons of self and informant EF reports were examined, for both patients and non-cancer controls. The extent of the concordance between patients’ reports and their caregivers’ reports was also determined.
PBT survivors and their caregivers reported more problems related to EF in contrast with the non-cancer comparison group (significant differences). There was a high level of agreement between patients’ and caregivers’ ratings within the patient group.
This study provides evidence suggesting that at an average of 3.67 (SD = 2.31) years following treatment for a PBT, EF difficulties are reported by patients and their caregivers. This study establishes a consistency between what is reported by survivors and what is reported by those who frequently interact with them. Further research investigating the link between these ratings and quality of life as well as other functions is encouraged.
Implications for Cancer Survivors
This study’s results demonstrate the importance of listening to PBT survivors’ perception of EF difficulties. While not confirmed by neuropsychological evaluations, the functional executive challenges reported by these survivors’ close relatives reflect what PBT survivors themselves report. Specialists should pay close attention to these difficulties to guarantee optimal post-cancer care.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981–98.
Petruzzi A, Finocchiaro CY, Lamperti E, Salmaggi A. Living with a brain tumor. Support Care Cancer. 2013;21(4):1105–11.
Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neuro-Oncol. 2017;131:525–46.
Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin. 2018;36(3):395–419.
Abu-Hegazy M, El-Hadaad HA. Neurocognitive effects of primary brain tumors. Neurooncology - newer developments. In Tech. 2016. 241-265.
Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression. Neuro Oncol. 2003;5(2):89–95.
Gehrke AK, Baisley MC, Sonck ALB, Wronski SL, Feuerstein M. Neurocognitive deficits following primary brain tumor treatment: systematic review of a decade of comparative studies. J Neuro-Oncol. 2013;115(2):135–42.
Godefroy O, Azouvi P, Robert P, Roussel M, LeGall D, Meulemans T. Dysexecutive syndrome: Diagnostic criteria and validation study. Ann Neurol. 2010;68(6):855–64.
Lezak P of NP and NMD, Lezak MD, Howieson AP of N and PDB, Howieson DB, Loring P of NDW, Loring DW, et al. Neuropsychological assessment. New York: Oxford University Press; 2004.
Ng JCH, See AAQ, Ang TY, Tan LYR, Ang BT, King NKK. Effects of surgery on neurocognitive function in patients with glioma: a meta-analysis of immediate post-operative and long-term follow-up neurocognitive outcomes. J Neuro-Oncol. 2019;141(1):167–82.
Abrey LE. The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. J Neuro-Oncol. 2012;108(2):285–90.
Lezak MD. The problem of assessing executive functions. Int J Psychol. 1982;17(1-4):281–97.
Miyake A, Friedman NP. The nature and organization of individual differences in executive functions: four general conclusions. Curr Dir Psychol Sci. 2012;21(1):8–14.
Baddeley A. The episodic buffer: a new component of working memory? Trends Cogn Sci. 2000;4(11):417–23.
Lieberman MD. Social: Why our brains are wired to connect. Oxford: Oxford University Press; 2013.
Gregg N, Arber A, Ashkan K, Brazil L, Bhangoo R, Beaney R, et al. Neurobehavioural changes in patients following brain tumour: patients and relatives perspective. Support Care Cancer. 2014;22(11):2965–72.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol Gen. 1992;121(1):15–23.
Shallice T, Broadbent DE, Weiskrantz L. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci. 1982;298(1089):199–209.
Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976;12(4):313–24.
Buchanan T. Self-report measures of executive function problems correlate with personality, not performance-based executive function measures, in nonclinical samples. Psychol Assess. 2016;28(4):372–85.
Eslinger PJ, Damasio AR. Severe disturbance of higher cognition after bilateral frontal lobe ablation: Patient EVR. Neurology. 1985;35(12):1731–41. https://doi.org/10.1212/WNL.35.12.1731.
Goldstein LH, Bernard S, Fenwick PB, Burgess PW, McNeil J. Unilateral frontal lobectomy can produce strategy application disorder. J Neurol Neurosurg Psychiatry. 1993;56(3):274–6.
Salthouse TA. Interrelations of aging, knowledge, and cognitive performance. In: Staudinger UM, Lindenberger U, editors. Understanding Human Development: Dialogues with Lifespan Psychology. Boston: Springer US; 2003. p. 265–87. https://doi.org/10.1007/978-1-4615-0357-6_12.
Burgess PW, Alderman N, Volle E, Benoit RG, Gilbert SJ. Mesulam’s frontal lobe mystery re-examined. Restor Neurol Neurosci. 2009;27(5):493–506.
Burgess PW, Alderman N, Evans J, Emslie H, Wilson BA. The ecological validity of tests of executive function. J Int Neuropsychol Soc. 1998;4(6):547–58.
Burgess PW, Alderman N, Forbes C, Costello A, Coates LM-A, Dawson DR, et al. The case for the development and use of “ecologically valid” measures of executive function in experimental and clinical neuropsychology. J Int Neuropsychol Soc. 2006;12(2):194–209.
Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive Function—Adult Version (BRIEF-A). Lutz, FL: Psychological Assesment Resources; 2005.
Burgess PW, Alderman N, Wilson BA, Evans JJ, Emslie H. Validity of the battery: Relationship between performance on the BADS and ratings of executive problems. In: Wilson BA, editor. BADS: Behavioural assessment of the dysexecutive syndrome manual. Bury St Edmunds: Thames Valley Test Company; 1996. p. 18–19.
Grace J, Malloy PF. Frontal Systems Behavior Scale (FrSBe): Professional manual. Lutz, FL: Psychological Assessment Resources; 2001.
Randolph JJ, Chaytor NS. Promoting the executive functions: Core foundations, assessment considerations, and practical applications. In: Randolph JJ, editor. Positive neuropsychology: Evidence-based perspectives on promoting cognitive health. New York: Springer; 2013.
Toplak ME, West RF, Stanovich KE. Practitioner review: Do performance-based measures and ratings of executive function assess the same construct? J Child Psychol Psychiatry. 2013;54(2):131–43.
Barkley RA, Murphy KR. The nature of executive function (EF) deficits in daily life activities in adults with ADHD and their relationship to performance on EF tests. J Psychopathol Behav Assess. 2011;33(2):137–58.
Chevignard MP, Soo C, Galvin J, Catroppa C, Eren S. Ecological assessment of cognitive functions in children with acquired brain injury: A systematic review. Brain Inj. 2012;26(9):1033–57.
Collins C, Gehrke A, Feuerstein M. Cognitive tasks challenging brain tumor survivors at work. J Occup Environ Med. 2013;55(12):1426–30.
Loughan AR, Braun SE, Lanoye A. Executive dysfunction in neuro-oncology: Behavior Rating Inventory of Executive Function in adult primary brain tumor patients. Appl Neuropsychol Adult. 2019;0(0):1-10.
Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010;52(2):219–27.
Molinari E, Mendoza TR, Gilbert MR. Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials. Neurooncol Pract. 2019;6(2):81–92.
Ediebah DE, Reijneveld JC, Taphoorn MJB, Coens C, Zikos E, Aaronson NK, et al. Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res. 2017;26(4):869–80.
Jacobs DI, Kumthekar P, Stell BV, Grimm SA, Rademaker AW, Rice L, et al. Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. Neurooncol Pract. 2014;1(2):47–54.
van der Linden SD, Gehring K, Baene WD, Emons WHM, Rutten G-JM, Sitskoorn MM. Assessment of executive functioning in patients with meningioma and low-grade glioma: a comparison of self-report, proxy-report, and test performance. J Int Neuropsychol Soc. 2020;26(2):187–96.
Folstein M. A practical method for grading the cognitive state of patients for the children. J Psychiatr Res. 1975;12:189–98.
Roy A, Besnard J, Lancelot C, Le Gall D. Adaptation and validation in French of the Behavior Rating Inventory of Executive Function- adult version (BRIEF-A). Paris: Hogrefe; 2015.
Ellenberg L, Liu Q, Gioia G, Yasui Y, Packer RJ, Mertens A, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study. Neuropsychology. 2009;23(6):705–17.
Tornås S, Løvstad M, Solbakk A-K, Evans J, Endestad T, Hol PK, et al. Rehabilitation of executive functions in patients with chronic acquired brain injury with goal management training, external cuing, and emotional regulation: A randomized controlled trial. J Int Neuropsychol Soc. 2016;22:436–52.
Society for Cognitive Rehabilitation. “What is cognitive rehabilitation?” 2013. www.societyforcognitiverehab.org. Accessed 15 Nov 2019
Leeper H, Milbury K. Survivorship care planning and implementation in neuro-oncology. Neuro-Oncology. 2018;20:vii40–6.
Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1533–42.
Richard NM, Bernstein LJ, Mason WP, Laperriere N, Maurice C, Millar B-A, et al. Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial. J Neuro-Oncol. 2019;142(3):565–75.
Tringale KR, Nguyen T, Bahrami N, Marshall DC, Leyden KM, Karunamuni R, et al. Identifying early diffusion imaging biomarkers of regional white matter injury as indicators of executive function decline following brain radiotherapy: A prospective clinical trial in primary brain tumor patients. Radiother Oncol. 2019;132:27–33.
Nicol C, Ownsworth T, Cubis L, Nguyen W, Foote M, Pinkham MB. Subjective cognitive functioning and associations with psychological distress in adult brain tumour survivors. J Cancer Surviv. 2019;13(5):653–62.
We wish to thank participants, families, and informants for their useful implication in this study.
We thank Hector Salcedo for his help in proofreading the current manuscript.
This study was supported by the French National Cancer Institute (INCa) (grant number SHSESP14- 14-041).
Conflicts of interest
The authors have no conflict of interest to declare.
The present study received French regulatory ethical approval (Comité de Protection des Personnes Ouest II, n°2015/27, ID-RCB n°2015-A01192-47) which includes the International Review Board Authorization (N°NCT02693405).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent to publish
Participants signed informed consent regarding publishing their data.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cantisano, N., Menei, P., Roualdes, V. et al. Patient-reported functional executive challenges and caregiver confirmation in adult brain tumor survivors. J Cancer Surviv (2020). https://doi.org/10.1007/s11764-020-00961-0
- Functional executive deficits
- Cancer survivorship
- Primary Brain Tumor (PBT)
- Cognitive late effects
- BRIEF-A concordance